Cancer causes & control : CCC · 2026
Survival among US adults with post-cancer-diagnosis cigarette smoking cessation.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Lihua, Zhang Wei, Pleis John R, Rossen Lauren M, He Yulei, Liu Bian
Аннотация
BACKGROUND: Current evidence on the impact of post-cancer-diagnosis cigarette smoking cessation on survival is largely based on small-scale studies with limited cancer types.
METHODS: This retrospective cohort study included 8,120 adult cancer survivors from the 2000-2018 National Health Interview Survey Public-use Linked Mortality Files with death information through December 31, 2019. We performed propensity score weighting (PSW) and survival analysis to assess the association of smoking cessation within 3 years after a cancer diagnosis with all-cause mortality among adult cancer survivors of all cancer types, cancers with high relative survival rates, and four major cancers (lung, breast, prostate, and colorectal).
RESULTS: Approximately 19.6% of cancer survivors who were cigarette smokers quit smoking within 3 years after their cancer diagnosis. Compared to those who did not quit, cancer survivors who quit had an additional median survival time (MST) of 4 (95% CI 3.1-4.9) years and a relatively lower risk of death (marginal hazard ratio (MHR) 0.86; 95% CI 0.76-0.98). A more pronounced survival benefit was found for survivors of cancers with a high 5-year relative survival rate (> 74%), where the quit group had a longer MST of 7 (95% CI 6.7-7.3) years and an MHR of 0.79 (95% CI 0.66-0.94). Except for colorectal cancer, significant survival benefits were also found for survivors of lung, prostate, and breast cancers.
CONCLUSION: By integrating PSW with linked nationally representative data spanning nearly two decades, we demonstrated that smoking cessation within 3 years after a cancer diagnosis was associated with a significant survival advantage.
METHODS: This retrospective cohort study included 8,120 adult cancer survivors from the 2000-2018 National Health Interview Survey Public-use Linked Mortality Files with death information through December 31, 2019. We performed propensity score weighting (PSW) and survival analysis to assess the association of smoking cessation within 3 years after a cancer diagnosis with all-cause mortality among adult cancer survivors of all cancer types, cancers with high relative survival rates, and four major cancers (lung, breast, prostate, and colorectal).
RESULTS: Approximately 19.6% of cancer survivors who were cigarette smokers quit smoking within 3 years after their cancer diagnosis. Compared to those who did not quit, cancer survivors who quit had an additional median survival time (MST) of 4 (95% CI 3.1-4.9) years and a relatively lower risk of death (marginal hazard ratio (MHR) 0.86; 95% CI 0.76-0.98). A more pronounced survival benefit was found for survivors of cancers with a high 5-year relative survival rate (> 74%), where the quit group had a longer MST of 7 (95% CI 6.7-7.3) years and an MHR of 0.79 (95% CI 0.66-0.94). Except for colorectal cancer, significant survival benefits were also found for survivors of lung, prostate, and breast cancers.
CONCLUSION: By integrating PSW with linked nationally representative data spanning nearly two decades, we demonstrated that smoking cessation within 3 years after a cancer diagnosis was associated with a significant survival advantage.